UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Antiprotozoal therapies

Author
Peter F Weller, MD, FACP
Section Editor
Karin Leder, MBBS, FRACP, PhD, MPH, DTMH
Deputy Editor
Elinor L Baron, MD, DTMH

INTRODUCTION

Protozoan parasites belong to four distinct groups: the amebae, the flagellates, the ciliates, and the sporozoa. Protozoa are single-celled organisms that replicate by various mechanisms within the infected host. The mechanisms of action of the various agents used to treat protozoan parasites are relatively poorly understood [1].

In the United States, the antiprotozoal drugs eflornithine, benznidazole, melarsoprol, nifurtimox, sodium stibogluconate, and suramin are available through the Centers for Disease Control and Prevention (CDC) Drug Service, Atlanta, GA 30333 (telephone 404-639-3670; drugservice@cdc.gov).

Agents with activity against protozoal parasites will be reviewed here; their use for treatment of specific protozoal infections is discussed in detail separately. Antimalarial agents are discussed in detail separately, as are agents with activity against helminths. (See "Antimalarial drugs: An overview" and "Anthelminthic therapies".)

ALBENDAZOLE

Albendazole binds to tubulin and affects cytoskeletal microtubules and is a well-established therapy treatment of helminthic infections [2]. (See "Anthelminthic therapies".)

Albendazole also has activity against some protozoan infections, including most microsporidial species, particularly Encephalitozoon infections. However, it is not as active against Enterocytozoon bieneusi [3-10]. (See "Microsporidiosis".)

                     

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Tue Jun 09 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Drugs for Parasitic Infections, 3rd Ed, The Medical Letter, New Rochelle, NY 2013.
  2. Lacey E. Mode of action of benzimidazoles. Parasitol Today 1990; 6:112.
  3. Blanshard C, Ellis DS, Tovey DG, et al. Treatment of intestinal microsporidiosis with albendazole in patients with AIDS. AIDS 1992; 6:311.
  4. Molina JM, Oksenhendler E, Beauvais B, et al. Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: clinical features and response to albendazole therapy. J Infect Dis 1995; 171:245.
  5. Weber R, Sauer B, Spycher MA, et al. Detection of Septata intestinalis in stool specimens and coprodiagnostic monitoring of successful treatment with albendazole. Clin Infect Dis 1994; 19:342.
  6. Dieterich DT, Lew EA, Kotler DP, et al. Treatment with albendazole for intestinal disease due to Enterocytozoon bieneusi in patients with AIDS. J Infect Dis 1994; 169:178.
  7. Asmuth DM, DeGirolami PC, Federman M, et al. Clinical features of microsporidiosis in patients with AIDS. Clin Infect Dis 1994; 18:819.
  8. Molina JM, Chastang C, Goguel J, et al. Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial. J Infect Dis 1998; 177:1373.
  9. Leder K, Ryan N, Spelman D, Crowe SM. Microsporidial disease in HIV-infected patients: a report of 42 patients and review of the literature. Scand J Infect Dis 1998; 30:331.
  10. Conteas CN, Berlin OG, Speck CE, et al. Modification of the clinical course of intestinal microsporidiosis in acquired immunodeficiency syndrome patients by immune status and anti-human immunodeficiency virus therapy. Am J Trop Med Hyg 1998; 58:555.
  11. Haile LG, Flaherty JF. Atovaquone: a review. Ann Pharmacother 1993; 27:1488.
  12. Dixon R, Pozniak AL, Watt HM, et al. Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. Antimicrob Agents Chemother 1996; 40:556.
  13. Denise H, Barrett MP. Uptake and mode of action of drugs used against sleeping sickness. Biochem Pharmacol 2001; 61:1.
  14. Kingsnorth AN. The chemotherapeutic potential of polyamine antimetabolites. Ann R Coll Surg Engl 1986; 68:76.
  15. Beauvais B, Sarfati C, Challier S, Derouin F. In vitro model to assess effect of antimicrobial agents on Encephalitozoon cuniculi. Antimicrob Agents Chemother 1994; 38:2440.
  16. Altamirano A, Bondani A. Adverse reactions to furazolidone and other drugs. A comparative review. Scand J Gastroenterol Suppl 1989; 169:70.
  17. American Academy of Pediatrics Committee on Drugs: Clioquinol (iodochlorhydroxyquin, vioform) and iodoquinol (diiodohydroxyquin): blindness and neuropathy. Pediatrics 1990; 86:797.
  18. de Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996; 348:1407.
  19. Wang CC. Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annu Rev Pharmacol Toxicol 1995; 35:93.
  20. Frayha GJ, Smyth JD, Gobert JG, Savel J. The mechanisms of action of antiprotozoal and anthelmintic drugs in man. Gen Pharmacol 1997; 28:273.
  21. Castro JA, Diaz de Toranzo EG. Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease). Biomed Environ Sci 1988; 1:19.
  22. Nitazoxanide (Alinia)--a new anti-protozoal agent. Med Lett Drugs Ther 2003; 45:29.
  23. Sands M, Kron MA, Brown RB. Pentamidine: a review. Rev Infect Dis 1985; 7:625.
  24. O'Brien JG, Dong BJ, Coleman RL, et al. A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia. Clin Infect Dis 1997; 24:854.
  25. Salamone FR, Cunha BA. Update on pentamidine for the treatment of Pneumocystis carinii pneumonia. Clin Pharm 1988; 7:501.
  26. Weiss LM, Perlman DC, Sherman J, et al. Isospora belli infection: treatment with pyrimethamine. Ann Intern Med 1988; 109:474.
  27. Herwaldt BL, Stokes SL, Juranek DD. American cutaneous leishmaniasis in U.S. travelers. Ann Intern Med 1993; 118:779.
  28. Pépin J, Milord F. The treatment of human African trypanosomiasis. Adv Parasitol 1994; 33:1.